Trials / Completed
CompletedNCT00380965
Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- Sponsor
- NEMA Research, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.
Detailed description
To determine the safety and efficacy of Cesamet™ in the symptomatic treatment of chemotherapy-induced neuropathic pain. This is a phase IV, multicenter, open label of Cesamet™ at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain. This study has two phases: A pretreatment phase and a treatment phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cesamet™ (nabilone) |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-09-27
- Last updated
- 2008-02-15
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00380965. Inclusion in this directory is not an endorsement.